Tarius SAC Tracker®


Background Analysis: US FDA Advisory Committees to Review Telesta Therapeutics’ MCNA for Bladder Cancer – NOV 18, 2015 (CTGTAC-ODAC)

The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.

The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held. 

To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.

Read more and subscribe here.

METADATA: Sponsor: Telesta Therapeutics, Inc. Drug Name: Mycobacterium phlei Cell wall-Nucleic Acid complex (MCNA) Drug Class: mycobacterial cell wall-DNA complex Indication: bladder cancer